The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
August 26th 2025
The sensor detects acetone levels in the breath to indicate diabetes.
First Treatment for All Genotypes of Hepatitis C in Pediatric Patients Granted FDA Approval
April 30th 2019The safety and efficacy of the glecaprevir and pibrentasvir in pediatric patients was evaluated during clinical trials of 47 patients with genotype 1, 2, 3 or 4 HCV infection without cirrhosis or with mild cirrhosis.
Read More
Study Shows Drug May Be New Treatment Option for Pediatric Patients with T2D
April 29th 2019Novo Nordisk announced the results of the ELLIPSE trial, which examined efficacy and safety and demonstrated superiority of liraglutide (Victoza) injection 1.8 mg vs placebo, in a presentation at the Pediatric Endocrine Society (PES)/Pediatric Academic Societies (PAS) Annual Meeting in Baltimore, MD, on Sunday.
Read More
Health Care Professionals Bring Drug Shortage Concerns to Capitol Hill
April 26th 2019Last week, National Association of EMS Physicians members joined with other health care professionals on Capitol Hil to bring attention to the issue of drug shortages, as emergency medical facilities across the country are forced to severely restrict use of certain IV fluids, anti-nausea medications, airway management medications, and other essential emergency medications (EEMs).
Read More
Teva Recalls 35 Lots of Bulk Losartan Potassium Tablets
April 26th 2019According to Teva, this recall was initiated by detection of an impurity – N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) – found in 6 lots of active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited that is above the FDA’s interim acceptable exposure limit.
Read More
ASHP Joins National Academy of Medicine Action Collaborative on Countering the US Opioid Epidemic
April 25th 2019The mission of the Action Collaborative is to convene and catalyze public, private, and nonprofit stakeholders to develop, curate, and disseminate multisector solutions designed to reduce opioid misuse and improve outcomes for individuals, families, and communities affected by the opioid crisis.
Read More
FDA Approves New Therapy for Moderate to Severe Plaque Psoriasis
April 24th 2019In clinical trials, AbbVie's risankizumab-rzaa produced high rates of durable skin clearance – most people (82 and 81%) treated with the drug achieved 90% skin clearance (PASI 90) at 1 year, with the majority (56 and 60%) achieving complete skin clearance (PASI 100).
Read More